Updates in Lung Cancer from ASCO 2016 Alectinib versus Crizotinib - - PDF document

▶
updates in lung cancer from asco 2016 alectinib versus
SMART_READER_LITE
LIVE PREVIEW

Updates in Lung Cancer from ASCO 2016 Alectinib versus Crizotinib - - PDF document

Mar 27, 2024 216 likes •569 views

7/20/2016 Updates in Lung Cancer from ASCO 2016 Alectinib versus Crizotinib in ALK Inhibitor Nave ALK-Positive Non-Small Cell Lung Cancer:<br /> Primary Results from the J-ALEX Study Presented By Hiroshi Nokihara at 2016 ASCO Annual

slide-1
SLIDE 1

7/20/2016 1

Updates in Lung Cancer from ASCO 2016

Alectinib versus Crizotinib in ALK Inhibitor Naïve ALK-Positive Non-Small Cell Lung Cancer:<br /> Primary Results from the J-ALEX Study

Presented By Hiroshi Nokihara at 2016 ASCO Annual Meeting

slide-2
SLIDE 2

7/20/2016 2

J-ALEX Phase III Study Design

Presented By Hiroshi Nokihara at 2016 ASCO Annual Meeting

Common AEs, ≥20% of Patients in Either Arm

Presented By Hiroshi Nokihara at 2016 ASCO Annual Meeting

slide-3
SLIDE 3

7/20/2016 3

Primary Endpoint: PFS by IRF (ITT Population)

Presented By Hiroshi Nokihara at 2016 ASCO Annual Meeting

Subgroup Analysis of PFS by IRF

Presented By Hiroshi Nokihara at 2016 ASCO Annual Meeting

slide-4
SLIDE 4

7/20/2016 4

Brigatinib in Patients With Crizotinib-Refractory ALK+ Non–Small Cell Lung Cancer: First Report of Efficacy and Safety From a Pivotal Randomized Phase 2 Trial (ALTA)

Presented By Dong-Wan Kim at 2016 ASCO Annual Meeting

Brigatinib Antitumor Activity by Arm

Presented By Dong-Wan Kim at 2016 ASCO Annual Meeting

slide-5
SLIDE 5

7/20/2016 5

PFS by Arm

Presented By Dong-Wan Kim at 2016 ASCO Annual Meeting

Survival by Arm

Presented By Dong-Wan Kim at 2016 ASCO Annual Meeting

slide-6
SLIDE 6

7/20/2016 6

Brigatinib CNS Antitumor Activity by Arm

Presented By Dong-Wan Kim at 2016 ASCO Annual Meeting

Safety and Efficacy of Lorlatinib (PF-06463922) From the Dose Escalation Component of a Study in Patients With Advanced ALK+ or ROS1+ Non-Small-Cell Lung Cancer

Presented By Benjamin Solomon at 2016 ASCO Annual Meeting

slide-7
SLIDE 7

7/20/2016 7

Phase I Design and Patient Population <br />of an Ongoing Phase I/II Study

Presented By Benjamin Solomon at 2016 ASCO Annual Meeting

Treatment-Related Adverse Events in <br />≥15% of Patients Treated at the RP2D

Presented By Benjamin Solomon at 2016 ASCO Annual Meeting

slide-8
SLIDE 8

7/20/2016 8

Clinical Activity: <br />Progression-Free Survival in ALK+ Patients

Presented By Benjamin Solomon at 2016 ASCO Annual Meeting

Majority of ROS1 Patients Had a <br />Decrease in Target Lesion Size*

Presented By Benjamin Solomon at 2016 ASCO Annual Meeting

slide-9
SLIDE 9

7/20/2016 9

CNS Responses in ALK/ROS1+ Patients<br />with Measurable Disease

Presented By Benjamin Solomon at 2016 ASCO Annual Meeting

Antitumor Activity and Safety of Crizotinib <br />in Patients with Advanced MET Exon 14-Altered <br />Non-Small Cell Lung Cancer

Presented By Alexander Drilon at 2016 ASCO Annual Meeting

slide-10
SLIDE 10

7/20/2016 10

Slide 11

Presented By Alexander Drilon at 2016 ASCO Annual Meeting

Osimertinib activity in patients with leptomeningeal disease from non-small cell lung cancer: <br />updated results from the BLOOM study

Presented By James Yang at 2016 ASCO Annual Meeting

slide-11
SLIDE 11

7/20/2016 11

BLOOM study design: osimertinib LM cohort 1

Presented By James Yang at 2016 ASCO Annual Meeting

Osimertinib activity across LM assessments

Presented By James Yang at 2016 ASCO Annual Meeting

slide-12
SLIDE 12

7/20/2016 12

Changes in EGFRm DNA copy number in CSF <br />with osimertinib treatment

Presented By James Yang at 2016 ASCO Annual Meeting

Phase I study (BLOOM) of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM)

Presented By Myung-Ju Ahn at 2016 ASCO Annual Meeting

slide-13
SLIDE 13

7/20/2016 13

Intracranial tumor shrinkage according to dose

Presented By Myung-Ju Ahn at 2016 ASCO Annual Meeting

An Open-Label Phase 2 Trial of Dabrafenib in Combination With Trametinib in Patients With Previously Treated BRAF V600E–Mutant Advanced <br />Non-Small Cell Lung Cancer (BRF113928)

Presented By David Planchard at 2016 ASCO Annual Meeting

slide-14
SLIDE 14

7/20/2016 14

Maximum Change in Target Lesion by Best Investigator-Assessed Confirmed Response

Presented By David Planchard at 2016 ASCO Annual Meeting

Progression-Free Survival

Presented By David Planchard at 2016 ASCO Annual Meeting

slide-15
SLIDE 15

7/20/2016 15

Most Common AEs (≥ 20%)

Presented By David Planchard at 2016 ASCO Annual Meeting

Slide 1

Presented By D. Camidge at 2016 ASCO Annual Meeting

slide-16
SLIDE 16

7/20/2016 16

Antibody Drug Conjugate: Sacituzumab Govitecan (IMMU-132)

Presented By D. Camidge at 2016 ASCO Annual Meeting

Adverse Events by Dose, All Causalities, All Grades in > 10% NSCLC Patients <br />and Grade 3+ in > 3% Patients (N=49 patients reporting at this time)

Presented By D. Camidge at 2016 ASCO Annual Meeting

slide-17
SLIDE 17

7/20/2016 17

Best Response By RECIST 1.1 (8 & 10 mg/kg)

Presented By D. Camidge at 2016 ASCO Annual Meeting

Trop-2 Staining and Best Initial Tumor Response (including unconfirmed responses)

Presented By D. Camidge at 2016 ASCO Annual Meeting

slide-18
SLIDE 18

7/20/2016 18

Progression-Free Survival and Overall Survival <br />(8 or 10 mg/kg; median of 3 prior therapies)

Presented By D. Camidge at 2016 ASCO Annual Meeting

Safety and efficacy of single agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC)

Presented By Charles Rudin at 2016 ASCO Annual Meeting

slide-19
SLIDE 19

7/20/2016 19

SCRX16-001: First-in-Human Study Schema

Presented By Charles Rudin at 2016 ASCO Annual Meeting

Adverse Event Profile in SCLC Subjects (n=74)

Presented By Charles Rudin at 2016 ASCO Annual Meeting

slide-20
SLIDE 20

7/20/2016 20

RECIST Confirmed Responses per Investigator

Presented By Charles Rudin at 2016 ASCO Annual Meeting

SCLC Kaplan-Meier Overall Survival

Presented By Charles Rudin at 2016 ASCO Annual Meeting

slide-21
SLIDE 21

7/20/2016 21

Favorable Comparison vs. Existing 2L and 3L CTX

Presented By Charles Rudin at 2016 ASCO Annual Meeting

CheckMate 012: Safety and Efficacy of First‐line Nivolumab and Ipilimumab in Advanced NSCLC

Presented By Matthew Hellmann at 2016 ASCO Annual Meeting

slide-22
SLIDE 22

7/20/2016 22

Phase 1 CheckMate 012 Study Design: <br />Nivolumab Plus Ipilimumab in First-line NSCLC

Presented By Matthew Hellmann at 2016 ASCO Annual Meeting

Nivolumab Plus Ipilimumab in First-line NSCLC:<br />Treatment-related Select AEs

Presented By Matthew Hellmann at 2016 ASCO Annual Meeting

slide-23
SLIDE 23

7/20/2016 23

Nivolumab Plus Ipilimumab in First-line NSCLC:<br />Summary of Efficacy

Presented By Matthew Hellmann at 2016 ASCO Annual Meeting

Nivolumab Plus Ipilimumab in First-line NSCLC:<br />Kinetics of Response

Presented By Matthew Hellmann at 2016 ASCO Annual Meeting

slide-24
SLIDE 24

7/20/2016 24

Nivolumab Plus Ipilimumab in First-line NSCLC:<br />Efficacy Across All Tumor PD-L1 Expression Levels

Presented By Matthew Hellmann at 2016 ASCO Annual Meeting

Local Consolidative Therapy (LCT) Improves Progression-Free Survival (PFS) in Patients with Oligometastatic Non-Small Cell Lung Cancer (NSCLC) who do not Progress after Front Line Systemic Therapy (FLST): Results of a Multi-Institutional Phase II Randomized Study

Presented By Daniel Gomez at 2016 ASCO Annual Meeting

slide-25
SLIDE 25

7/20/2016 25

Trial Design

Presented By Daniel Gomez at 2016 ASCO Annual Meeting

Trial Design

Presented By Daniel Gomez at 2016 ASCO Annual Meeting

slide-26
SLIDE 26

7/20/2016 26

PFS Outcomes (updated data)

Presented By Daniel Gomez at 2016 ASCO Annual Meeting

Prognostic Factors for PFS

Presented By Daniel Gomez at 2016 ASCO Annual Meeting

slide-27
SLIDE 27

7/20/2016 27

Time to New Site Failure (TNSF)

Presented By Daniel Gomez at 2016 ASCO Annual Meeting

Improved Overall Survival in Lung Cancer Patients <br />using a Webapplication-mediated Follow-up compared to Standard Modalities: <br />Results of a Phase III Randomized Trial

Presented By Fabrice Denis at 2016 ASCO Annual Meeting

slide-28
SLIDE 28

7/20/2016 28

Phase 3 multi-centric randomized study

Presented By Fabrice Denis at 2016 ASCO Annual Meeting

Overall Survival Improvement

Presented By Fabrice Denis at 2016 ASCO Annual Meeting

slide-29
SLIDE 29

7/20/2016 29

Quality of Life (mean score at 6 months)

Presented By Fabrice Denis at 2016 ASCO Annual Meeting

Other « intensive » clinical follow-up studies

Presented By Fabrice Denis at 2016 ASCO Annual Meeting

slide-30
SLIDE 30

7/20/2016 30

Slide 1

Presented By Heather Wakelee at 2016 ASCO Annual Meeting

Slide 2

Presented By Heather Wakelee at 2016 ASCO Annual Meeting

slide-31
SLIDE 31

7/20/2016 31

E1505 OS +/- Bevacizumab E1505 DFS+/- Bevacizumab

Presented By Heather Wakelee at 2016 ASCO Annual Meeting

Pooled Chemo Analysis (all patients regardless of treatment arm)<br /> OS by chemo group OS by chemo group <br />Non-squamous : Logrank p=0.18 Squamous: Logrank p=0.99

Presented By Heather Wakelee at 2016 ASCO Annual Meeting

slide-32
SLIDE 32

7/20/2016 32

Pooled Chemo Analysis (all patients regardless of treatment arm)<br /> DFS by chemo group DFS by chemo group <br />Non-squamous : Logrank p=0.58 Squamous : Logrank p=0.83

Presented By Heather Wakelee at 2016 ASCO Annual Meeting

CONVERT trial<br />Concurrent ONce-daily VErsus twice-daily RadioTherapy: A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and
  • nce-daily radiotherapy schedules in patients with limited-stage small cell lung cancer and good performance status

Presented By Corinne Faivre-Finn at 2016 ASCO Annual Meeting

slide-33
SLIDE 33

7/20/2016 33

Study design multinational, phase III randomised study

Presented By Corinne Faivre-Finn at 2016 ASCO Annual Meeting

Overall survival

Presented By Corinne Faivre-Finn at 2016 ASCO Annual Meeting

slide-34
SLIDE 34

7/20/2016 34

Progression free <br />survival

Presented By Corinne Faivre-Finn at 2016 ASCO Annual Meeting

Acute Toxicity

Presented By Corinne Faivre-Finn at 2016 ASCO Annual Meeting

slide-35
SLIDE 35

7/20/2016 35